Corpus
PascalFrancis
Racine
Corpus
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur les relations entre la France et l'Australie

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

First international pharmacoeconomic conference on Alzheimer's disease : Report and summary : International working group for the harmonization of dementia drug guidelines report

Identifieur interne : 006479 ( PascalFrancis/Corpus ); précédent : 006478; suivant : 006480

First international pharmacoeconomic conference on Alzheimer's disease : Report and summary : International working group for the harmonization of dementia drug guidelines report

Auteurs : P. J. Whitehouse ; B. Winblad ; D. Shostak ; A. Bhattacharjya ; M. Brod ; H. Brodaty ; A. Dor ; H. Feldman ; F. Forette ; S. Gauthier ; J. Hay ; C. Henke ; S. Hill ; V. Mastey ; P. Neumann ; B. O'Brien ; K. Pugner ; M. Sano ; T. Sawada ; R. Stone ; A. Wimo

Source :

RBID : Pascal:99-0062866

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0893-0341
A02 01      @0 ADADE2
A03   1    @0 Alzheimer dis. assoc. disord.
A05       @2 12
A06       @2 4
A08 01  1  ENG  @1 First international pharmacoeconomic conference on Alzheimer's disease : Report and summary : International working group for the harmonization of dementia drug guidelines report
A11 01  1    @1 WHITEHOUSE (P. J.)
A11 02  1    @1 WINBLAD (B.)
A11 03  1    @1 SHOSTAK (D.)
A11 04  1    @1 BHATTACHARJYA (A.)
A11 05  1    @1 BROD (M.)
A11 06  1    @1 BRODATY (H.)
A11 07  1    @1 DOR (A.)
A11 08  1    @1 FELDMAN (H.)
A11 09  1    @1 FORETTE (F.)
A11 10  1    @1 GAUTHIER (S.)
A11 11  1    @1 HAY (J.)
A11 12  1    @1 HENKE (C.)
A11 13  1    @1 HILL (S.)
A11 14  1    @1 MASTEY (V.)
A11 15  1    @1 NEUMANN (P.)
A11 16  1    @1 O'BRIEN (B.)
A11 17  1    @1 PUGNER (K.)
A11 18  1    @1 SANO (M.)
A11 19  1    @1 SAWADA (T.)
A11 20  1    @1 STONE (R.)
A11 21  1    @1 WIMO (A.)
A14 01      @1 Alzheimer Center at Fairhill Center for Aging, Case Western Reserve University @2 Cleveland, Ohio @3 USA @Z 1 aut. @Z 7 aut.
A14 02      @1 Department of Clinical Neuroscience and Family Medicine, Karolinska Institute, Division of Geriatric Medicine, Huddinge Hospital @2 Huddinge @3 SWE @Z 2 aut.
A14 03      @1 Institute for Alternative Futures @2 Alexandria, Virginia @3 USA @Z 3 aut.
A14 04      @1 Health Economics, Janssen Research Foundation @2 Titusville, New Jersey @3 USA @Z 4 aut.
A14 05      @1 Centre for Clinical Aging Services Research, University of California-San Francisco @2 San Francisco, California @3 USA @Z 5 aut.
A14 06      @1 Department of Psychogeriatrics, University of New South Wales, Prince Henry Hospital @2 Sydney @3 AUS @Z 6 aut.
A14 07      @1 Division of Neurology, University of British Columbia @2 Vancouver @3 CAN @Z 8 aut.
A14 08      @1 Hopital Broca, Fondation National de Geronotologie @2 Paris @3 FRA @Z 9 aut.
A14 09      @1 Center for Studies in Aging, McGill University @2 Montreal, Quebec @3 CAN @Z 10 aut.
A14 10      @1 Department of Pharmaceutical Economics and Policy, University of Southern California @2 Los Angeles, California, U.S.A @3 USA @Z 11 aut.
A14 11      @1 Lewin-TAG @2 San Francisco, California @3 USA @Z 12 aut.
A14 12      @1 Faculty of Medicine and Health Sciences, University of Newcastle @2 Callaghan, Newcastle, New South Wales @3 AUS @Z 13 aut.
A14 13      @1 Pfizer Pharmaceuticals Group, Pfizer Inc. @2 New York, New York @3 USA @Z 14 aut.
A14 14      @1 Department of Health Policy and Management, Harvard School of Public Health @2 Boston, Massachusetts @3 USA @Z 15 aut.
A14 15      @1 Department of Clinical Epidemiology and Biostatistics, McMaster University and Centre for Evaluation of Medicines, St Joseph's Hospital @2 Hamilton, Ontario @3 CAN @Z 16 aut.
A14 16      @1 Economists Advisory Group Ltd @2 London @3 GBR @Z 17 aut.
A14 17      @1 Clinical Neuropsychology, Gertrude H. Sergievsky Center, College of Physicians and Surgeons of Columbia University @2 New York, New York @3 USA @Z 18 aut.
A14 18      @1 BF Research Institute @2 Osaka @3 JPN @Z 19 aut.
A14 19      @1 International Longevity Center-USA @2 New York, New York @3 USA @Z 20 aut.
A14 20      @1 Department of Family Medicine, Umeå University @3 SWE @Z 21 aut.
A14 21      @1 Division of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute @2 Stockholm @3 SWE @Z 21 aut.
A20       @1 266-280
A21       @1 1998
A23 01      @0 ENG
A43 01      @1 INIST @2 21377 @5 354000073305420020
A44       @0 0000 @1 © 1999 INIST-CNRS. All rights reserved.
A45       @0 1 p.1/2
A47 01  1    @0 99-0062866
A60       @1 P
A61       @0 A
A64   1    @0 Alzheimer disease and associated disorders
A66 01      @0 USA
C02 01  X    @0 002B30A01A1
C03 01  X  FRE  @0 Démence Alzheimer @5 01
C03 01  X  ENG  @0 Alzheimer disease @5 01
C03 01  X  SPA  @0 Demencia Alzheimer @5 01
C03 02  X  FRE  @0 Analyse coût efficacité @5 04
C03 02  X  ENG  @0 Cost efficiency analysis @5 04
C03 02  X  SPA  @0 Análisis costo eficacia @5 04
C03 03  X  FRE  @0 Qualité vie @5 07
C03 03  X  ENG  @0 Quality of life @5 07
C03 03  X  SPA  @0 Calidad vida @5 07
C03 04  X  FRE  @0 Aidant @5 10
C03 04  X  ENG  @0 Caregiver @5 10
C03 04  X  SPA  @0 Ayudante a domicilio @5 10
C03 05  X  FRE  @0 Utilisation @5 11
C03 05  X  ENG  @0 Use @5 11
C03 05  X  GER  @0 Gebrauch @5 11
C03 05  X  SPA  @0 Utilización @5 11
C03 06  X  FRE  @0 Ressource @5 12
C03 06  X  ENG  @0 Resource @5 12
C03 06  X  SPA  @0 Recurso @5 12
C03 07  X  FRE  @0 Essai clinique @5 13
C03 07  X  ENG  @0 Clinical trial @5 13
C03 07  X  SPA  @0 Ensayo clínico @5 13
C03 08  X  FRE  @0 Chimiothérapie @5 14
C03 08  X  ENG  @0 Chemotherapy @5 14
C03 08  X  SPA  @0 Quimioterapia @5 14
C03 09  X  FRE  @0 Modèle économique @5 16
C03 09  X  ENG  @0 Economic model @5 16
C03 09  X  SPA  @0 Modelo económico @5 16
C03 10  X  FRE  @0 Economie santé @5 17
C03 10  X  ENG  @0 Health economy @5 17
C03 10  X  SPA  @0 Economía salud @5 17
C03 11  X  FRE  @0 Santé publique @5 18
C03 11  X  ENG  @0 Public health @5 18
C03 11  X  SPA  @0 Salud pública @5 18
C03 12  X  FRE  @0 Méthodologie @5 19
C03 12  X  ENG  @0 Methodology @5 19
C03 12  X  SPA  @0 Metodología @5 19
C03 13  X  FRE  @0 Homme @5 20
C03 13  X  ENG  @0 Human @5 20
C03 13  X  SPA  @0 Hombre @5 20
C03 14  X  FRE  @0 Impact économique @5 23
C03 14  X  ENG  @0 Economic impact @5 23
C03 14  X  SPA  @0 Impacto económico @5 23
C07 01  X  FRE  @0 Système nerveux pathologie @5 37
C07 01  X  ENG  @0 Nervous system diseases @5 37
C07 01  X  SPA  @0 Sistema nervioso patología @5 37
C07 02  X  FRE  @0 Système nerveux central pathologie @5 38
C07 02  X  ENG  @0 Central nervous system disease @5 38
C07 02  X  SPA  @0 Sistema nervosio central patología @5 38
C07 03  X  FRE  @0 Encéphale pathologie @5 39
C07 03  X  ENG  @0 Cerebral disorder @5 39
C07 03  X  SPA  @0 Encéfalo patología @5 39
C07 04  X  FRE  @0 Maladie dégénérative @5 40
C07 04  X  ENG  @0 Degenerative disease @5 40
C07 04  X  SPA  @0 Enfermedad degenerativa @5 40
N21       @1 032

Format Inist (serveur)

NO : PASCAL 99-0062866 INIST
ET : First international pharmacoeconomic conference on Alzheimer's disease : Report and summary : International working group for the harmonization of dementia drug guidelines report
AU : WHITEHOUSE (P. J.); WINBLAD (B.); SHOSTAK (D.); BHATTACHARJYA (A.); BROD (M.); BRODATY (H.); DOR (A.); FELDMAN (H.); FORETTE (F.); GAUTHIER (S.); HAY (J.); HENKE (C.); HILL (S.); MASTEY (V.); NEUMANN (P.); O'BRIEN (B.); PUGNER (K.); SANO (M.); SAWADA (T.); STONE (R.); WIMO (A.)
AF : Alzheimer Center at Fairhill Center for Aging, Case Western Reserve University/Cleveland, Ohio/Etats-Unis (1 aut., 7 aut.); Department of Clinical Neuroscience and Family Medicine, Karolinska Institute, Division of Geriatric Medicine, Huddinge Hospital/Huddinge/Suède (2 aut.); Institute for Alternative Futures/Alexandria, Virginia/Etats-Unis (3 aut.); Health Economics, Janssen Research Foundation/Titusville, New Jersey/Etats-Unis (4 aut.); Centre for Clinical Aging Services Research, University of California-San Francisco/San Francisco, California/Etats-Unis (5 aut.); Department of Psychogeriatrics, University of New South Wales, Prince Henry Hospital/Sydney/Australie (6 aut.); Division of Neurology, University of British Columbia/Vancouver/Canada (8 aut.); Hopital Broca, Fondation National de Geronotologie/Paris/France (9 aut.); Center for Studies in Aging, McGill University/Montreal, Quebec/Canada (10 aut.); Department of Pharmaceutical Economics and Policy, University of Southern California/Los Angeles, California, U.S.A/Etats-Unis (11 aut.); Lewin-TAG/San Francisco, California/Etats-Unis (12 aut.); Faculty of Medicine and Health Sciences, University of Newcastle/Callaghan, Newcastle, New South Wales/Australie (13 aut.); Pfizer Pharmaceuticals Group, Pfizer Inc./New York, New York/Etats-Unis (14 aut.); Department of Health Policy and Management, Harvard School of Public Health/Boston, Massachusetts/Etats-Unis (15 aut.); Department of Clinical Epidemiology and Biostatistics, McMaster University and Centre for Evaluation of Medicines, St Joseph's Hospital/Hamilton, Ontario/Canada (16 aut.); Economists Advisory Group Ltd/London/Royaume-Uni (17 aut.); Clinical Neuropsychology, Gertrude H. Sergievsky Center, College of Physicians and Surgeons of Columbia University/New York, New York/Etats-Unis (18 aut.); BF Research Institute/Osaka/Japon (19 aut.); International Longevity Center-USA/New York, New York/Etats-Unis (20 aut.); Department of Family Medicine, Umeå University/Suède (21 aut.); Division of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute/Stockholm/Suède (21 aut.)
DT : Publication en série; Niveau analytique
SO : Alzheimer disease and associated disorders; ISSN 0893-0341; Coden ADADE2; Etats-Unis; Da. 1998; Vol. 12; No. 4; Pp. 266-280; Bibl. 1 p.1/2
LA : Anglais
CC : 002B30A01A1
FD : Démence Alzheimer; Analyse coût efficacité; Qualité vie; Aidant; Utilisation; Ressource; Essai clinique; Chimiothérapie; Modèle économique; Economie santé; Santé publique; Méthodologie; Homme; Impact économique
FG : Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Maladie dégénérative
ED : Alzheimer disease; Cost efficiency analysis; Quality of life; Caregiver; Use; Resource; Clinical trial; Chemotherapy; Economic model; Health economy; Public health; Methodology; Human; Economic impact
EG : Nervous system diseases; Central nervous system disease; Cerebral disorder; Degenerative disease
GD : Gebrauch
SD : Demencia Alzheimer; Análisis costo eficacia; Calidad vida; Ayudante a domicilio; Utilización; Recurso; Ensayo clínico; Quimioterapia; Modelo económico; Economía salud; Salud pública; Metodología; Hombre; Impacto económico
LO : INIST-21377.354000073305420020
ID : 99-0062866

Links to Exploration step

Pascal:99-0062866

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">First international pharmacoeconomic conference on Alzheimer's disease : Report and summary : International working group for the harmonization of dementia drug guidelines report</title>
<author>
<name sortKey="Whitehouse, P J" sort="Whitehouse, P J" uniqKey="Whitehouse P" first="P. J." last="Whitehouse">P. J. Whitehouse</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Alzheimer Center at Fairhill Center for Aging, Case Western Reserve University</s1>
<s2>Cleveland, Ohio</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Winblad, B" sort="Winblad, B" uniqKey="Winblad B" first="B." last="Winblad">B. Winblad</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Clinical Neuroscience and Family Medicine, Karolinska Institute, Division of Geriatric Medicine, Huddinge Hospital</s1>
<s2>Huddinge</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Shostak, D" sort="Shostak, D" uniqKey="Shostak D" first="D." last="Shostak">D. Shostak</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Institute for Alternative Futures</s1>
<s2>Alexandria, Virginia</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Bhattacharjya, A" sort="Bhattacharjya, A" uniqKey="Bhattacharjya A" first="A." last="Bhattacharjya">A. Bhattacharjya</name>
<affiliation>
<inist:fA14 i1="04">
<s1>Health Economics, Janssen Research Foundation</s1>
<s2>Titusville, New Jersey</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Brod, M" sort="Brod, M" uniqKey="Brod M" first="M." last="Brod">M. Brod</name>
<affiliation>
<inist:fA14 i1="05">
<s1>Centre for Clinical Aging Services Research, University of California-San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Brodaty, H" sort="Brodaty, H" uniqKey="Brodaty H" first="H." last="Brodaty">H. Brodaty</name>
<affiliation>
<inist:fA14 i1="06">
<s1>Department of Psychogeriatrics, University of New South Wales, Prince Henry Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Dor, A" sort="Dor, A" uniqKey="Dor A" first="A." last="Dor">A. Dor</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Alzheimer Center at Fairhill Center for Aging, Case Western Reserve University</s1>
<s2>Cleveland, Ohio</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Feldman, H" sort="Feldman, H" uniqKey="Feldman H" first="H." last="Feldman">H. Feldman</name>
<affiliation>
<inist:fA14 i1="07">
<s1>Division of Neurology, University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Forette, F" sort="Forette, F" uniqKey="Forette F" first="F." last="Forette">F. Forette</name>
<affiliation>
<inist:fA14 i1="08">
<s1>Hopital Broca, Fondation National de Geronotologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Gauthier, S" sort="Gauthier, S" uniqKey="Gauthier S" first="S." last="Gauthier">S. Gauthier</name>
<affiliation>
<inist:fA14 i1="09">
<s1>Center for Studies in Aging, McGill University</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Hay, J" sort="Hay, J" uniqKey="Hay J" first="J." last="Hay">J. Hay</name>
<affiliation>
<inist:fA14 i1="10">
<s1>Department of Pharmaceutical Economics and Policy, University of Southern California</s1>
<s2>Los Angeles, California, U.S.A</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Henke, C" sort="Henke, C" uniqKey="Henke C" first="C." last="Henke">C. Henke</name>
<affiliation>
<inist:fA14 i1="11">
<s1>Lewin-TAG</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Hill, S" sort="Hill, S" uniqKey="Hill S" first="S." last="Hill">S. Hill</name>
<affiliation>
<inist:fA14 i1="12">
<s1>Faculty of Medicine and Health Sciences, University of Newcastle</s1>
<s2>Callaghan, Newcastle, New South Wales</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Mastey, V" sort="Mastey, V" uniqKey="Mastey V" first="V." last="Mastey">V. Mastey</name>
<affiliation>
<inist:fA14 i1="13">
<s1>Pfizer Pharmaceuticals Group, Pfizer Inc.</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Neumann, P" sort="Neumann, P" uniqKey="Neumann P" first="P." last="Neumann">P. Neumann</name>
<affiliation>
<inist:fA14 i1="14">
<s1>Department of Health Policy and Management, Harvard School of Public Health</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="O Brien, B" sort="O Brien, B" uniqKey="O Brien B" first="B." last="O'Brien">B. O'Brien</name>
<affiliation>
<inist:fA14 i1="15">
<s1>Department of Clinical Epidemiology and Biostatistics, McMaster University and Centre for Evaluation of Medicines, St Joseph's Hospital</s1>
<s2>Hamilton, Ontario</s2>
<s3>CAN</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Pugner, K" sort="Pugner, K" uniqKey="Pugner K" first="K." last="Pugner">K. Pugner</name>
<affiliation>
<inist:fA14 i1="16">
<s1>Economists Advisory Group Ltd</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Sano, M" sort="Sano, M" uniqKey="Sano M" first="M." last="Sano">M. Sano</name>
<affiliation>
<inist:fA14 i1="17">
<s1>Clinical Neuropsychology, Gertrude H. Sergievsky Center, College of Physicians and Surgeons of Columbia University</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Sawada, T" sort="Sawada, T" uniqKey="Sawada T" first="T." last="Sawada">T. Sawada</name>
<affiliation>
<inist:fA14 i1="18">
<s1>BF Research Institute</s1>
<s2>Osaka</s2>
<s3>JPN</s3>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Stone, R" sort="Stone, R" uniqKey="Stone R" first="R." last="Stone">R. Stone</name>
<affiliation>
<inist:fA14 i1="19">
<s1>International Longevity Center-USA</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Wimo, A" sort="Wimo, A" uniqKey="Wimo A" first="A." last="Wimo">A. Wimo</name>
<affiliation>
<inist:fA14 i1="20">
<s1>Department of Family Medicine, Umeå University</s1>
<s3>SWE</s3>
<sZ>21 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation>
<inist:fA14 i1="21">
<s1>Division of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>21 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">99-0062866</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 99-0062866 INIST</idno>
<idno type="RBID">Pascal:99-0062866</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">006479</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">First international pharmacoeconomic conference on Alzheimer's disease : Report and summary : International working group for the harmonization of dementia drug guidelines report</title>
<author>
<name sortKey="Whitehouse, P J" sort="Whitehouse, P J" uniqKey="Whitehouse P" first="P. J." last="Whitehouse">P. J. Whitehouse</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Alzheimer Center at Fairhill Center for Aging, Case Western Reserve University</s1>
<s2>Cleveland, Ohio</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Winblad, B" sort="Winblad, B" uniqKey="Winblad B" first="B." last="Winblad">B. Winblad</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Clinical Neuroscience and Family Medicine, Karolinska Institute, Division of Geriatric Medicine, Huddinge Hospital</s1>
<s2>Huddinge</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Shostak, D" sort="Shostak, D" uniqKey="Shostak D" first="D." last="Shostak">D. Shostak</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Institute for Alternative Futures</s1>
<s2>Alexandria, Virginia</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Bhattacharjya, A" sort="Bhattacharjya, A" uniqKey="Bhattacharjya A" first="A." last="Bhattacharjya">A. Bhattacharjya</name>
<affiliation>
<inist:fA14 i1="04">
<s1>Health Economics, Janssen Research Foundation</s1>
<s2>Titusville, New Jersey</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Brod, M" sort="Brod, M" uniqKey="Brod M" first="M." last="Brod">M. Brod</name>
<affiliation>
<inist:fA14 i1="05">
<s1>Centre for Clinical Aging Services Research, University of California-San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Brodaty, H" sort="Brodaty, H" uniqKey="Brodaty H" first="H." last="Brodaty">H. Brodaty</name>
<affiliation>
<inist:fA14 i1="06">
<s1>Department of Psychogeriatrics, University of New South Wales, Prince Henry Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Dor, A" sort="Dor, A" uniqKey="Dor A" first="A." last="Dor">A. Dor</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Alzheimer Center at Fairhill Center for Aging, Case Western Reserve University</s1>
<s2>Cleveland, Ohio</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Feldman, H" sort="Feldman, H" uniqKey="Feldman H" first="H." last="Feldman">H. Feldman</name>
<affiliation>
<inist:fA14 i1="07">
<s1>Division of Neurology, University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Forette, F" sort="Forette, F" uniqKey="Forette F" first="F." last="Forette">F. Forette</name>
<affiliation>
<inist:fA14 i1="08">
<s1>Hopital Broca, Fondation National de Geronotologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Gauthier, S" sort="Gauthier, S" uniqKey="Gauthier S" first="S." last="Gauthier">S. Gauthier</name>
<affiliation>
<inist:fA14 i1="09">
<s1>Center for Studies in Aging, McGill University</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Hay, J" sort="Hay, J" uniqKey="Hay J" first="J." last="Hay">J. Hay</name>
<affiliation>
<inist:fA14 i1="10">
<s1>Department of Pharmaceutical Economics and Policy, University of Southern California</s1>
<s2>Los Angeles, California, U.S.A</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Henke, C" sort="Henke, C" uniqKey="Henke C" first="C." last="Henke">C. Henke</name>
<affiliation>
<inist:fA14 i1="11">
<s1>Lewin-TAG</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Hill, S" sort="Hill, S" uniqKey="Hill S" first="S." last="Hill">S. Hill</name>
<affiliation>
<inist:fA14 i1="12">
<s1>Faculty of Medicine and Health Sciences, University of Newcastle</s1>
<s2>Callaghan, Newcastle, New South Wales</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Mastey, V" sort="Mastey, V" uniqKey="Mastey V" first="V." last="Mastey">V. Mastey</name>
<affiliation>
<inist:fA14 i1="13">
<s1>Pfizer Pharmaceuticals Group, Pfizer Inc.</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Neumann, P" sort="Neumann, P" uniqKey="Neumann P" first="P." last="Neumann">P. Neumann</name>
<affiliation>
<inist:fA14 i1="14">
<s1>Department of Health Policy and Management, Harvard School of Public Health</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="O Brien, B" sort="O Brien, B" uniqKey="O Brien B" first="B." last="O'Brien">B. O'Brien</name>
<affiliation>
<inist:fA14 i1="15">
<s1>Department of Clinical Epidemiology and Biostatistics, McMaster University and Centre for Evaluation of Medicines, St Joseph's Hospital</s1>
<s2>Hamilton, Ontario</s2>
<s3>CAN</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Pugner, K" sort="Pugner, K" uniqKey="Pugner K" first="K." last="Pugner">K. Pugner</name>
<affiliation>
<inist:fA14 i1="16">
<s1>Economists Advisory Group Ltd</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Sano, M" sort="Sano, M" uniqKey="Sano M" first="M." last="Sano">M. Sano</name>
<affiliation>
<inist:fA14 i1="17">
<s1>Clinical Neuropsychology, Gertrude H. Sergievsky Center, College of Physicians and Surgeons of Columbia University</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Sawada, T" sort="Sawada, T" uniqKey="Sawada T" first="T." last="Sawada">T. Sawada</name>
<affiliation>
<inist:fA14 i1="18">
<s1>BF Research Institute</s1>
<s2>Osaka</s2>
<s3>JPN</s3>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Stone, R" sort="Stone, R" uniqKey="Stone R" first="R." last="Stone">R. Stone</name>
<affiliation>
<inist:fA14 i1="19">
<s1>International Longevity Center-USA</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Wimo, A" sort="Wimo, A" uniqKey="Wimo A" first="A." last="Wimo">A. Wimo</name>
<affiliation>
<inist:fA14 i1="20">
<s1>Department of Family Medicine, Umeå University</s1>
<s3>SWE</s3>
<sZ>21 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation>
<inist:fA14 i1="21">
<s1>Division of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>21 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Alzheimer disease and associated disorders</title>
<title level="j" type="abbreviated">Alzheimer dis. assoc. disord.</title>
<idno type="ISSN">0893-0341</idno>
<imprint>
<date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Alzheimer disease and associated disorders</title>
<title level="j" type="abbreviated">Alzheimer dis. assoc. disord.</title>
<idno type="ISSN">0893-0341</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Alzheimer disease</term>
<term>Caregiver</term>
<term>Chemotherapy</term>
<term>Clinical trial</term>
<term>Cost efficiency analysis</term>
<term>Economic impact</term>
<term>Economic model</term>
<term>Health economy</term>
<term>Human</term>
<term>Methodology</term>
<term>Public health</term>
<term>Quality of life</term>
<term>Resource</term>
<term>Use</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Démence Alzheimer</term>
<term>Analyse coût efficacité</term>
<term>Qualité vie</term>
<term>Aidant</term>
<term>Utilisation</term>
<term>Ressource</term>
<term>Essai clinique</term>
<term>Chimiothérapie</term>
<term>Modèle économique</term>
<term>Economie santé</term>
<term>Santé publique</term>
<term>Méthodologie</term>
<term>Homme</term>
<term>Impact économique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0893-0341</s0>
</fA01>
<fA02 i1="01">
<s0>ADADE2</s0>
</fA02>
<fA03 i2="1">
<s0>Alzheimer dis. assoc. disord.</s0>
</fA03>
<fA05>
<s2>12</s2>
</fA05>
<fA06>
<s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>First international pharmacoeconomic conference on Alzheimer's disease : Report and summary : International working group for the harmonization of dementia drug guidelines report</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>WHITEHOUSE (P. J.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>WINBLAD (B.)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>SHOSTAK (D.)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>BHATTACHARJYA (A.)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>BROD (M.)</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>BRODATY (H.)</s1>
</fA11>
<fA11 i1="07" i2="1">
<s1>DOR (A.)</s1>
</fA11>
<fA11 i1="08" i2="1">
<s1>FELDMAN (H.)</s1>
</fA11>
<fA11 i1="09" i2="1">
<s1>FORETTE (F.)</s1>
</fA11>
<fA11 i1="10" i2="1">
<s1>GAUTHIER (S.)</s1>
</fA11>
<fA11 i1="11" i2="1">
<s1>HAY (J.)</s1>
</fA11>
<fA11 i1="12" i2="1">
<s1>HENKE (C.)</s1>
</fA11>
<fA11 i1="13" i2="1">
<s1>HILL (S.)</s1>
</fA11>
<fA11 i1="14" i2="1">
<s1>MASTEY (V.)</s1>
</fA11>
<fA11 i1="15" i2="1">
<s1>NEUMANN (P.)</s1>
</fA11>
<fA11 i1="16" i2="1">
<s1>O'BRIEN (B.)</s1>
</fA11>
<fA11 i1="17" i2="1">
<s1>PUGNER (K.)</s1>
</fA11>
<fA11 i1="18" i2="1">
<s1>SANO (M.)</s1>
</fA11>
<fA11 i1="19" i2="1">
<s1>SAWADA (T.)</s1>
</fA11>
<fA11 i1="20" i2="1">
<s1>STONE (R.)</s1>
</fA11>
<fA11 i1="21" i2="1">
<s1>WIMO (A.)</s1>
</fA11>
<fA14 i1="01">
<s1>Alzheimer Center at Fairhill Center for Aging, Case Western Reserve University</s1>
<s2>Cleveland, Ohio</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Department of Clinical Neuroscience and Family Medicine, Karolinska Institute, Division of Geriatric Medicine, Huddinge Hospital</s1>
<s2>Huddinge</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Institute for Alternative Futures</s1>
<s2>Alexandria, Virginia</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04">
<s1>Health Economics, Janssen Research Foundation</s1>
<s2>Titusville, New Jersey</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05">
<s1>Centre for Clinical Aging Services Research, University of California-San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06">
<s1>Department of Psychogeriatrics, University of New South Wales, Prince Henry Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07">
<s1>Division of Neurology, University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08">
<s1>Hopital Broca, Fondation National de Geronotologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="09">
<s1>Center for Studies in Aging, McGill University</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="10">
<s1>Department of Pharmaceutical Economics and Policy, University of Southern California</s1>
<s2>Los Angeles, California, U.S.A</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="11">
<s1>Lewin-TAG</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="12">
<s1>Faculty of Medicine and Health Sciences, University of Newcastle</s1>
<s2>Callaghan, Newcastle, New South Wales</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="13">
<s1>Pfizer Pharmaceuticals Group, Pfizer Inc.</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="14">
<s1>Department of Health Policy and Management, Harvard School of Public Health</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="15">
<s1>Department of Clinical Epidemiology and Biostatistics, McMaster University and Centre for Evaluation of Medicines, St Joseph's Hospital</s1>
<s2>Hamilton, Ontario</s2>
<s3>CAN</s3>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="16">
<s1>Economists Advisory Group Ltd</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>17 aut.</sZ>
</fA14>
<fA14 i1="17">
<s1>Clinical Neuropsychology, Gertrude H. Sergievsky Center, College of Physicians and Surgeons of Columbia University</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>18 aut.</sZ>
</fA14>
<fA14 i1="18">
<s1>BF Research Institute</s1>
<s2>Osaka</s2>
<s3>JPN</s3>
<sZ>19 aut.</sZ>
</fA14>
<fA14 i1="19">
<s1>International Longevity Center-USA</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>20 aut.</sZ>
</fA14>
<fA14 i1="20">
<s1>Department of Family Medicine, Umeå University</s1>
<s3>SWE</s3>
<sZ>21 aut.</sZ>
</fA14>
<fA14 i1="21">
<s1>Division of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>21 aut.</sZ>
</fA14>
<fA20>
<s1>266-280</s1>
</fA20>
<fA21>
<s1>1998</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>21377</s2>
<s5>354000073305420020</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>1 p.1/2</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>99-0062866</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i2="1">
<s0>Alzheimer disease and associated disorders</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X">
<s0>002B30A01A1</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Démence Alzheimer</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Alzheimer disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Demencia Alzheimer</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Analyse coût efficacité</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Cost efficiency analysis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Análisis costo eficacia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Qualité vie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Quality of life</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Calidad vida</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Aidant</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Caregiver</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Ayudante a domicilio</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Utilisation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Use</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="GER">
<s0>Gebrauch</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Utilización</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Ressource</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Resource</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Recurso</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Essai clinique</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Clinical trial</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Ensayo clínico</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Chimiothérapie</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Chemotherapy</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Quimioterapia</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Modèle économique</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Economic model</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Modelo económico</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Economie santé</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Health economy</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Economía salud</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Santé publique</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Public health</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Salud pública</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Méthodologie</s0>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Methodology</s0>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>Metodología</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE">
<s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG">
<s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA">
<s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE">
<s0>Impact économique</s0>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG">
<s0>Economic impact</s0>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA">
<s0>Impacto económico</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fN21>
<s1>032</s1>
</fN21>
</pA>
</standard>
<server>
<NO>PASCAL 99-0062866 INIST</NO>
<ET>First international pharmacoeconomic conference on Alzheimer's disease : Report and summary : International working group for the harmonization of dementia drug guidelines report</ET>
<AU>WHITEHOUSE (P. J.); WINBLAD (B.); SHOSTAK (D.); BHATTACHARJYA (A.); BROD (M.); BRODATY (H.); DOR (A.); FELDMAN (H.); FORETTE (F.); GAUTHIER (S.); HAY (J.); HENKE (C.); HILL (S.); MASTEY (V.); NEUMANN (P.); O'BRIEN (B.); PUGNER (K.); SANO (M.); SAWADA (T.); STONE (R.); WIMO (A.)</AU>
<AF>Alzheimer Center at Fairhill Center for Aging, Case Western Reserve University/Cleveland, Ohio/Etats-Unis (1 aut., 7 aut.); Department of Clinical Neuroscience and Family Medicine, Karolinska Institute, Division of Geriatric Medicine, Huddinge Hospital/Huddinge/Suède (2 aut.); Institute for Alternative Futures/Alexandria, Virginia/Etats-Unis (3 aut.); Health Economics, Janssen Research Foundation/Titusville, New Jersey/Etats-Unis (4 aut.); Centre for Clinical Aging Services Research, University of California-San Francisco/San Francisco, California/Etats-Unis (5 aut.); Department of Psychogeriatrics, University of New South Wales, Prince Henry Hospital/Sydney/Australie (6 aut.); Division of Neurology, University of British Columbia/Vancouver/Canada (8 aut.); Hopital Broca, Fondation National de Geronotologie/Paris/France (9 aut.); Center for Studies in Aging, McGill University/Montreal, Quebec/Canada (10 aut.); Department of Pharmaceutical Economics and Policy, University of Southern California/Los Angeles, California, U.S.A/Etats-Unis (11 aut.); Lewin-TAG/San Francisco, California/Etats-Unis (12 aut.); Faculty of Medicine and Health Sciences, University of Newcastle/Callaghan, Newcastle, New South Wales/Australie (13 aut.); Pfizer Pharmaceuticals Group, Pfizer Inc./New York, New York/Etats-Unis (14 aut.); Department of Health Policy and Management, Harvard School of Public Health/Boston, Massachusetts/Etats-Unis (15 aut.); Department of Clinical Epidemiology and Biostatistics, McMaster University and Centre for Evaluation of Medicines, St Joseph's Hospital/Hamilton, Ontario/Canada (16 aut.); Economists Advisory Group Ltd/London/Royaume-Uni (17 aut.); Clinical Neuropsychology, Gertrude H. Sergievsky Center, College of Physicians and Surgeons of Columbia University/New York, New York/Etats-Unis (18 aut.); BF Research Institute/Osaka/Japon (19 aut.); International Longevity Center-USA/New York, New York/Etats-Unis (20 aut.); Department of Family Medicine, Umeå University/Suède (21 aut.); Division of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute/Stockholm/Suède (21 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Alzheimer disease and associated disorders; ISSN 0893-0341; Coden ADADE2; Etats-Unis; Da. 1998; Vol. 12; No. 4; Pp. 266-280; Bibl. 1 p.1/2</SO>
<LA>Anglais</LA>
<CC>002B30A01A1</CC>
<FD>Démence Alzheimer; Analyse coût efficacité; Qualité vie; Aidant; Utilisation; Ressource; Essai clinique; Chimiothérapie; Modèle économique; Economie santé; Santé publique; Méthodologie; Homme; Impact économique</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Maladie dégénérative</FG>
<ED>Alzheimer disease; Cost efficiency analysis; Quality of life; Caregiver; Use; Resource; Clinical trial; Chemotherapy; Economic model; Health economy; Public health; Methodology; Human; Economic impact</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Degenerative disease</EG>
<GD>Gebrauch</GD>
<SD>Demencia Alzheimer; Análisis costo eficacia; Calidad vida; Ayudante a domicilio; Utilización; Recurso; Ensayo clínico; Quimioterapia; Modelo económico; Economía salud; Salud pública; Metodología; Hombre; Impacto económico</SD>
<LO>INIST-21377.354000073305420020</LO>
<ID>99-0062866</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006479 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 006479 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:99-0062866
   |texte=   First international pharmacoeconomic conference on Alzheimer's disease : Report and summary : International working group for the harmonization of dementia drug guidelines report
}}
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024